MONTREAL, Sept. 4, 2025 /PRNewswire/ -- Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, ...
Congruence pulls in $50M series A to build a team of 'drug hunters' to go after rare disease targets
A new biotech called Congruence Therapeutics snagged $50 million to build a new team of "drug hunters" focused on protein misfolding to go after rare diseases. Congruence Therapeutics just completed a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results